Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sinovac 23-valent pneumococcal polysaccharide vaccine
- Development stage
- Phase 4
- Lead developer
- Sinovac Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
The **Sinovac 23-valent pneumococcal polysaccharide vaccine (PPV23)** is a vaccine developed by Sinovac Biotech Co., Ltd. containing purified capsular polysaccharides from 23 serotypes of *Streptococcus pneumoniae* (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F), which account for 85-90% of pneumococcal infections. It induces humoral immunity by stimulating B-cell production of serotype-specific IgG antibodies that opsonize bacteria for phagocytosis, providing protection against invasive pneumococcal disease, pneumonia, and bacteremia. Approved by China's NMPA for individuals aged ≥2 years, it demonstrates non-inferior immunogenicity and safety to commercial PPV23 vaccines in phase III trials, with robust antibody responses (2-fold increase rates 49.71-90.96%) persisting up to 6 years, good lot-to-lot consistency, and a favorable safety profile (mostly mild adverse reactions).[1][3][5][7][9][10]
- Brand names
- Sinovac PPV23
- Other names
- Sinovac PPV23
02
Targets
CPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on Sinovac 23-valent pneumococcal polysaccharide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sinovac 23-valent pneumococcal polysaccharide vaccine.